Astellas Pharma took a big step into gene therapies when it announced an agreement at the end of 2019 to acquire Audentes Therapeutics for $3 billion. The company continues to build on that acquisition and has just completed construction on a 154,000 square foot, state-of the art cell and gene therapy facility to bring together teams dispersed across 20 locations. We spoke Ha Tran, medical head of cell and gene therapy for Astellas Pharma, about the company’s vision for cell and gene therapies, its efforts to restart trials for its X-linked myotubular myopathy gene therapy, and how it is looking to other programs beyond that.
Targeting a Common Pathway in Genetic Forms of Obesity
After Pruning Orchard, Gaspar Focuses on High Value Opportunities
Writing a New Chapter of Genetic Medicine
How an Ultra-Rare Disease Patient Organization Drove Research to a Treatment
With a New Identity, Travere Thearpeutics Seeks to Find Its True Path
Making Gene Therapies Accessible to Patient with Ultra-Rare Conditions
Using RNA Therapies to Target Inherited Retinal Diseases
Part 4-Gene Therapy: A Researcher’s Perspective
Part 3-Gene Therapy: An Industry Perspective
Part 2-Gene Therapy: A Patient Advocate's Perspective
Part 1-Gene Therapy: A Genetic Counselor’s Perspective
An App to Make Patients the Experts in their Own Conditions
Pursuing a New Target for Autoimmune Diseases
Finding a Rare Friend
Industrializing Individual Therapies for People with Rare Conditions
Rare Disease Advocate Turned Filmmaker Turns Lens on his Son
Inhibiting Signaling that Drives Growth of Rare Malformations
Readying a Rare Disease Community for the Availability of Treatments
Forging a Rare Disease Research Agenda
Delivering Injectable Drugs Orally
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money